- Home
- SKIN vs HURA Comparison
SKIN vs HURA Comparison
Compare SKIN & HURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SKIN | HURA |
|---|---|---|
| Founded | 1997 | 2009 |
| Country | United States | United States |
| Employees | N/A | 22 |
| Industry | Package Goods/Cosmetics | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 123.9M | 144.3M |
| IPO Year | 2020 | N/A |
Fundamental Metrics
Financial Performance| Metric | SKIN | HURA |
|---|---|---|
| Price | $0.93 | $2.53 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 2 |
| Target Price | $2.03 | ★ $9.50 |
| AVG Volume (30 Days) | 678.6K | ★ 1.3M |
| Earning Date | 05-07-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 55.56 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $300,790,000.00 | N/A |
| Revenue This Year | $0.88 | N/A |
| Revenue Next Year | $4.60 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.76 | $0.41 |
| 52 Week High | $2.69 | $4.05 |
Technical Indicators
Market Signals| Indicator | SKIN | HURA |
|---|---|---|
| Relative Strength Index (RSI) | 51.78 | 57.31 |
| Support Level | $0.87 | $2.26 |
| Resistance Level | $1.22 | $2.63 |
| Average True Range (ATR) | 0.07 | 0.25 |
| MACD | 0.01 | -0.04 |
| Stochastic Oscillator | 77.70 | 44.15 |
Price Performance
Historical ComparisonAbout SKIN The Beauty Health Company
The Beauty Health Co is a category-creating beauty health company that along with its subsidiaries designs, develops, manufactures, markets and sells esthetic technologies and products. The company's brand portfolio includes Hydrafacial, SkinStylus, and Keravive, offering Syndeo device, SkinStylus SteriLock Microsystem, Keravive Peptide Solution and other products.
About HURA TuHURA Biosciences Inc.
TuHURA Biosciences Inc is a Phase 3 registration stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. It is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda (pembrolizumab) in first-line treatment for advanced or metastatic Merkel Cell Carcinoma.